Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen

摘要

This present invention provides a broad immunotherapeutic method for treating a living patient afflicted with superficial bladder cancer, where the patient has failed at least one immunostimulatory therapeutic treatment attempt previously. The invention also offers a first-time immunotherapeutic method for treating a living patient afflicted with upper urinary tract cancer, the ureter and renal pelvis regions of the body, an anatomic location where no effective cancer treatment has been available before. The methodology introduces an effective quantity of at least one viable uMicobacterium/u species to the chosen anatomic site concurrently and in combination with at least one selective cytokine chosen from the group consisting of any type or isoform of interferon-alpha, interferon-beta, interferon-gamma, interleukin-1, interleukin-2, interleukin-3, interleukin-12, interleukin-15, and interleukin-18.